We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Medtronic (MDT - Free Report) was down 1.16% at $87.10. This change lagged the S&P 500's daily gain of 0.8%. On the other hand, the Dow registered a loss of 0.15%, and the technology-centric Nasdaq increased by 1.6%.
Coming into today, shares of the medical device company had lost 0.36% in the past month. In that same time, the Medical sector lost 0.77%, while the S&P 500 gained 5.15%.
Market participants will be closely following the financial results of Medtronic in its upcoming release. The company plans to announce its earnings on June 3, 2026. On that day, Medtronic is projected to report earnings of $1.6 per share, which would represent a year-over-year decline of 1.23%. Meanwhile, the latest consensus estimate predicts the revenue to be $9.66 billion, indicating a 8.2% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.58 per share and a revenue of $36.13 billion, representing changes of +1.64% and +7.72%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Medtronic. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. As of now, Medtronic holds a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is currently trading at a Forward P/E ratio of 15.78. This denotes a discount relative to the industry average Forward P/E of 19.49.
Also, we should mention that MDT has a PEG ratio of 2.28. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.64.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 165, finds itself in the bottom 33% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Medtronic (MDT - Free Report) was down 1.16% at $87.10. This change lagged the S&P 500's daily gain of 0.8%. On the other hand, the Dow registered a loss of 0.15%, and the technology-centric Nasdaq increased by 1.6%.
Coming into today, shares of the medical device company had lost 0.36% in the past month. In that same time, the Medical sector lost 0.77%, while the S&P 500 gained 5.15%.
Market participants will be closely following the financial results of Medtronic in its upcoming release. The company plans to announce its earnings on June 3, 2026. On that day, Medtronic is projected to report earnings of $1.6 per share, which would represent a year-over-year decline of 1.23%. Meanwhile, the latest consensus estimate predicts the revenue to be $9.66 billion, indicating a 8.2% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.58 per share and a revenue of $36.13 billion, representing changes of +1.64% and +7.72%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Medtronic. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. As of now, Medtronic holds a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is currently trading at a Forward P/E ratio of 15.78. This denotes a discount relative to the industry average Forward P/E of 19.49.
Also, we should mention that MDT has a PEG ratio of 2.28. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Products industry held an average PEG ratio of 1.64.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 165, finds itself in the bottom 33% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.